Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors

被引:49
作者
Yao, Yiwu [1 ]
Liao, Chenzhong [2 ]
Li, Zheng [3 ]
Wang, Zhen [1 ]
Sun, Qiao [1 ]
Liu, Chunping [1 ]
Yang, Yang [2 ]
Tu, Zhengchao [1 ]
Jiang, Sheng [1 ]
机构
[1] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Med Chem Lab, Guangzhou 510530, Guangdong, Peoples R China
[2] Hefei Univ Technol, Sch Med Engn, Hefei 230009, Anhui, Peoples R China
[3] Methodist Hosp, Res Inst, Houston, TX 77030 USA
基金
中国国家自然科学基金;
关键词
HDAC; Isoforms selectivity; Structure-activity relationship; Scaffold-hopping; ZINC-BINDING; EXPRESSION; CANCER; HDAC; DISCOVERY; POTENT; SELECTIVITY; VITRO;
D O I
10.1016/j.ejmech.2014.09.024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of HDAC inhibitors demonstrating class I and IIb subtype selectivity have been identified using a scaffold-hopping strategy. Several designed compounds showed better selectivity for class I and IIb over class IIa HDAC isoforms comparing to the FDA approved HDAC targeting drug SAHA. A representative lead compound 22 bearing a biphenyl moiety demonstrated promising class I and IIb HDAC isoforms selectivity and in vitro anticancer activities against several cancer cell lines. This work could serve as a fundamental platform for further exploration of selective HDAC inhibitors using designed molecular scaffold. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:639 / 652
页数:14
相关论文
共 40 条
  • [1] Epigenetic protein families: a new frontier for drug discovery
    Arrowsmith, Cheryl H.
    Bountra, Chas
    Fish, Paul V.
    Lee, Kevin
    Schapira, Matthieu
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (05) : 384 - 400
  • [2] Inside HDAC with HDAC inhibitors
    Bertrand, Philippe
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) : 2095 - 2116
  • [3] Potent Histone Deacetylase Inhibitors Derived from 4-(Aminomethyl)-N-hydroxybenzamide with High Selectivity for the HDAC6 Isoform
    Blackburn, Christopher
    Barrett, Cynthia
    Chin, Janice
    Garcia, Kris
    Gigstad, Kenneth
    Gould, Alexandra
    Gutierrez, Juan
    Harrison, Sean
    Hoar, Kara
    Lynch, Chrissie
    Rowland, R. Scott
    Tsu, Chris
    Ringeling, John
    Xu, He
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (18) : 7201 - 7211
  • [4] Histone deacetylase inhibitors in cancer treatment:: A review of the clinical toxicity and the modulation of gene expression in cancer cells
    Bruserud, O.
    Stapnes, C.
    Ersvaer, E.
    Gjertsen, B. T.
    Ryningen, A.
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2007, 8 (06) : 388 - 400
  • [5] Computational Exploration of Zinc Binding Groups for HDAC Inhibition
    Chen, Kai
    Xu, Liping
    Wiest, Olaf
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2013, 78 (10) : 5051 - 5055
  • [6] Histone deacetylases (HDACs): characterization of the classical HDAC family
    De Ruijter, AJM
    Van Gennip, AH
    Caron, HN
    Kemp, S
    Van Kuilenburg, ABP
    [J]. BIOCHEMICAL JOURNAL, 2003, 370 : 737 - 749
  • [7] Giannini G, 2012, FUTURE MED CHEM, V4, P1439, DOI [10.4155/FMC.12.80, 10.4155/fmc.12.80]
  • [8] Vorinostat
    Grant, Steven
    Easley, Chris
    Kirkpatrick, Peter
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (01) : 21 - 22
  • [9] Discovery and Extensive in Vitro Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising Lead
    Hou, Jingli
    Li, Zhonghua
    Fang, Qinghong
    Feng, Congran
    Zhang, Hanwen
    Guo, Weikang
    Wang, Huihui
    Gu, Guoxian
    Tian, Yinping
    Liu, Pi
    Liu, Ruihua
    Lin, Jianping
    Shi, Yi-kang
    Yin, Zheng
    Shen, Jie
    Wang, Peng George
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (07) : 3066 - 3075
  • [10] Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
    Johnstone, RW
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 287 - 299